SRI Krishna Pharmaceuticals Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: SRI Krishna Pharmaceuticals Limited Pharmaceutical Export Portfolio Dataset — 6 Products, $31.4M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

SRI Krishna Pharmaceuticals Limited — Pharmaceutical Exporter Profile (2026) | 6 Products, $31.4M Trade | TransData Nexus

SRI Krishna Pharmaceuticals Limited

Indian Pharmaceutical Exporter · Analgesics & Antipyretics Specialist · $31.4M Total Trade · DGFT Verified

SRI Krishna Pharmaceuticals Limited is an Indian pharmaceutical exporter with a total trade value of $31.4M across 6 products in 3 therapeutic categories. Based on 705 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Paracetamol ($10.6M), Amino ($7.8M), Acetaminophen ($6.9M).

SRI Krishna Pharmaceuticals Limited — Export Portfolio & Destination Treemap

SRI Krishna Pharmaceuticals Limited pharmaceutical export portfolio — 6 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is SRI Krishna Pharmaceuticals Limited? — Company Overview & Market Position

Established on September 26, 1974, Sri Krishna Pharmaceuticals Limited (SKPL) is a prominent Indian pharmaceutical company headquartered in Hyderabad, Telangana. The company operates as a public limited entity, classified as a non-government company limited by shares, with a Corporate Identification Number (CIN) of U24230TG1974PLC001790. SKPL specializes in the bulk manufacture of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and finished dosage forms, including tablets, capsules, syrups, and injections.

As of the latest available data, the company has an authorized capital of ₹150 million and a paid-up capital of ₹119.185 million. While specific revenue figures are not publicly disclosed, SKPL has a workforce ranging from 501 to 1,000 employees, reflecting its substantial operational scale. The company's official website, www.srikrishnapharma.com, provides comprehensive information about its products, services, and regulatory certifications.

What Does SRI Krishna Pharmaceuticals Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Paracetamol$10.6M

Product Portfolio — Top 6 by Export Value

SRI Krishna Pharmaceuticals Limited exports 6 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Paracetamol	Analgesics & Antipyretics	$10.6M	212	3.0%	5
2	Amino	Nutritional Supplements	$7.8M	155	2.4%	3
3	Acetaminophen	Analgesics & Antipyretics	$6.9M	138	3.0%	3
4	Tramadol	Analgesics & Antipyretics	$3.2M	111	0.8%	12
5	Loperamide	Gastrointestinal	$1.9M	67	2.5%	5
6	Aspirin	Analgesics & Antipyretics	$1.1M	22	2.9%	9

SRI Krishna Pharmaceuticals Limited exports 6 pharmaceutical products across 3 therapeutic categories with a total export value of $31.4M. The top category is Analgesics & Antipyretics (69.4% of portfolio), followed by Nutritional Supplements (24.7%), indicating a concentrated portfolio with the top 5 products accounting for 96.5% of total export value.

SRI Krishna Pharmaceuticals Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

SKPL operates multiple manufacturing facilities across Telangana and Maharashtra, each dedicated to specific product lines to ensure specialized production. These facilities are equipped with modern equipment and adhere to stringent Good Manufacturing Practice (GMP) standards. Notably, the company's Unit I has been inspected and approved by the US FDA, Therapeutic Goods Administration (TGA) of Australia, and the World Health Organization (WHO) for the production of Acetaminophen (Paracetamol) and Domperidone. Additionally, Unit II has received GMP compliance certificates from German, Brazilian (ANVISA), and Mexican (COFEPRIS) regulatory authorities.

3Key Leadership

As of the latest available information, the key managerial personnel at Sri Krishna Pharmaceuticals Limited include:

Nikhil Bihari Pandey: Chief Financial Officer (CFO)
Kalluru Manaswini: Company Secretary

These executives play pivotal roles in steering the company's strategic direction and ensuring compliance with regulatory standards.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does SRI Krishna Pharmaceuticals Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Sri Krishna Pharmaceuticals Limited has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities have undergone inspections and received approvals from various regulatory bodies:

United States: The US FDA has approved SKPL's facilities for the production of Acetaminophen (Paracetamol) and Domperidone.

European Union: The European Directorate for the Quality of Medicines & HealthCare (EDQM) has granted Certificates of Suitability (CEP) for products such as Acetaminophen, Domperidone, and Folic Acid.

Australia: The Therapeutic Goods Administration (TGA) has recognized SKPL's facilities for compliance with GMP standards.

United Kingdom: The Medicines and Healthcare products Regulatory Agency (MHRA) has approved SKPL's facilities for the production of various pharmaceutical products.

SRI Krishna Pharmaceuticals Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Sri Krishna Pharmaceuticals Limited's facilities have been inspected and approved by the US Food and Drug Administration (FDA) for the production of Acetaminophen (Paracetamol) and Domperidone. The company holds multiple Drug Master Files (DMFs) for various products, including Glipizide, Phenylephrine, Meclizine, and Doxylamine Succinate. These approvals and filings reflect SKPL's adherence to FDA standards and its capability to supply products to the US market.

2WHO & EU GMP

SKPL's commitment to quality is demonstrated through its certifications from the World Health Organization (WHO) and the European Directorate for the Quality of Medicines & HealthCare (EDQM). The company has obtained Certificates of Suitability (CEP) from EDQM for products such as Acetaminophen, Domperidone, and Folic Acid. These certifications affirm SKPL's compliance with international quality standards, enhancing its reputation in global markets.

3CDSCO & Indian Regulatory

SRI Krishna Pharmaceuticals Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the global pharmaceutical industry, Sri Krishna Pharmaceuticals Limited faces competition from both domestic and international manufacturers. Key competitors include companies such as Aurobindo Pharma, Dr. Reddy's Laboratories, and Sun Pharmaceutical Industries, which also offer a range of APIs and finished dosage forms. While specific market share data is not available, SKPL's focus on quality, regulatory compliance, and a diversified product portfolio positions it as a competitive player in the industry.

2Key Differentiators

Sri Krishna Pharmaceuticals Limited distinguishes itself through its vertical integration, encompassing the production of APIs, PFIs, and finished dosage forms. This integration allows for greater control over the manufacturing process and product quality. The company's commitment to quality is further evidenced by its certifications from various regulatory bodies, including the US FDA, WHO, and EDQM. Additionally, SKPL's expansion into nutraceuticals reflects its adaptability and responsiveness to market trends.

3Strategic Position

Buyer Due Diligence Brief — Evaluating SRI Krishna Pharmaceuticals Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Sri Krishna Pharmaceuticals Limited has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products. The company's export volume and consistency are supported by its regulatory certifications and approvals from various international bodies. Indicators of reliability include adherence to GMP standards, successful inspections by regulatory authorities, and a diversified product portfolio catering to multiple therapeutic categories.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA: Confirm facility registrations and approved Drug Master Files (DMFs) through the FDA's official database.

WHO-GMP: Obtain certification details from

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — SRI Krishna Pharmaceuticals Limited

How many pharmaceutical products does SRI Krishna Pharmaceuticals Limited export from India?

SRI Krishna Pharmaceuticals Limited exports 6 pharmaceutical products across 3 therapeutic categories. The top exports are Paracetamol ($10.6M), Amino ($7.8M), Acetaminophen ($6.9M), Tramadol ($3.2M), Loperamide ($1.9M). Total export value is $31.4M.

What is SRI Krishna Pharmaceuticals Limited's total pharmaceutical export value?

SRI Krishna Pharmaceuticals Limited's total pharmaceutical export value is $31.4M, based on 705 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does SRI Krishna Pharmaceuticals Limited cover?

SRI Krishna Pharmaceuticals Limited exports across 3 therapeutic categories. The largest are Analgesics & Antipyretics (69.4%, 4 products), Nutritional Supplements (24.7%, 1 products), Gastrointestinal (6.0%, 1 products).

Get Full SRI Krishna Pharmaceuticals Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.